三生製藥(01530.HK):購回500萬歐元可換股債券
格隆匯4月20日丨三生製藥(01530.HK)公佈,有關3億歐元於2022年到期的零票息可換股債券,於2020年10月16日,公司透過場外市場根據債券的條款及條件按債券面值購回本金總額為500萬歐元的債券。就債券購回的已付總買入價為525.5萬歐元(包括中介費)。緊隨債券購回後,發行在外的債券本金額為2.95億歐元。假設發行在外的債券按當前轉換價每股換股股份14.28港元悉數轉換,發行在外的債券將轉換為約1.85億股換股股份,佔公司於公告日期的已發行股本約7.30%及公司於公告日期經悉數轉換髮行在外的債券發行換股股份而擴大的已發行股本約6.80%。
公司的財務狀況穩健。董事會相信,債券購回可削減公司的債務,進一步改善公司的財務狀況,從而節省利息付款及贖回溢價付款,同時,降低債券的可能轉換對公司股權的潛在攤薄影響。董事會相信,債券購回符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.